Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 883-892

  Leblond, Pierre ^a   Boulet, Elodie ^a   Bal Mahieu, Christine ^a   Pillon, Arnaud ^b   Kruczynski, Anna ^b   Guilbaud, Nicolas ^b   Bailly, Christian ^b   Sarrazin, Thierry ^a   Lartigau, Eric ^a   Lansiaux, Amélie ^a   Meignan, Samuel ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

F14512; Neuroblastoma; Pediatric high grade glioma; Polyamine transport system; Topoisomerase II inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; F14512; MELPHALAN; PODOPHYLLOTOXIN; SPERMINE;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; GLIOMA; HUMAN; IONIZING RADIATION; LIVER NEOPLASMS; NEUROBLASTOMA; PATHOLOGY; RADIATION RESPONSE; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; LIVER NEOPLASMS; MELPHALAN; MICE, INBRED BALB C; NEUROBLASTOMA; PODOPHYLLOTOXIN; RADIATION, IONIZING; SPERMINE;

EID: 84930738639     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0132-3     Document Type: Article

References (22)

1. Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 9(7):400-413
2. Ladenstein R, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, Forjaz De Lacerda A, Beck Popovic M, Bician P, Garami M, Trahair T, Pearson A, Valteau Couanet D (2011) Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. J Clin Oncol (Meeting Abstracts) 29 (18-suppl 2)
3. Pegg AE (1988) Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 48(4):759-774
4. Casero RA Jr, Woster PM (2009) Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem 52(15):4551-4573
5. Barret JM, Kruczynski A, Vispe S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C (2008) F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 68(23):9845-9853
6. Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 50(15):3240-3249
7. Annereau JP, Brel V, Dumontet C, Guminski Y, Imbert T, Broussas M, Vispe S, Breand S, Guilbaud N, Barret JM, Bailly C (2010) A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. Leuk Res 34(10):1383-1389
8. Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N (2011) Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. Invest New Drugs 29(1):9-21
9. Kruczynski A, Pillon A, Creancier L, Vandenberghe I, Gomes B, Brel V, Fournier E, Annereau JP, Currie E, Guminski Y, Bonnet D, Bailly C, Guilbaud N (2013) F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. Leukemia
10. De Botton S, Berthon C, Bulabois C, Prebet T, Vey N, Chevallier P (2012) F14512 a novel polyamine-vectorized anti-cancer drug targeting topoisomerase II in adults patients with acute myeloid leukemia (AML): results from a Phase 1 study. EHA 17th Congress, Amsterdam, pp 14-17
11. De Botton S, Quesnel B, Audoly L, Bailly C, Brandely-Talbol M, Provendier O, Bahleda R, Soria J (2014) Tackling leukemia: Phase 1 study of F14512 in relapsed or refractory AML patients. 12th International Congress on Targeted Anticancer Therapies, Washington
12. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C (2009) Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS ONE 4(4):e5209
13. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT (1998) Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41(6):437-447
14. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
15. Chastagner P, Bouffet E, Grill J, Kalifa C (2001) What have we learnt from previous phase II trials to help in the management of childhood brain tumours? Eur J Cancer 37(16):1981-1993
16. Seiler N, Delcros JG, Moulinoux JP (1996) Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 28(8):843-861
17. Brel V, Annereau JP, Vispe S, Kruczynski A, Bailly C, Guilbaud N (2011) Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. Biochem Pharmacol 82(12):1843-1852
18. Ballot C, Jendoubi M, Kluza J, Jonneaux A, Laine W, Formstecher P, Bailly C, Marchetti P (2012) Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II. Apoptosis 17(4):364-376
19. Guminski Y, Grousseaud M, Cugnasse S, Brel V, Annereau JP, Vispe S, Guilbaud N, Barret JM, Bailly C, Imbert T (2009) Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system. Bioorg Med Chem Lett 19(9):2474-2477
20. Mouawad F, Gros A, Rysman B, Bal-Mahieu C, Bertheau C, Horn S, Sarrazin T, Lartigau E, Chevalier D, Bailly C, Lansiaux A, Meignan S (2014) The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. Oral Oncol 50(2):113-119
21. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
22. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305(5931):245-248